John A Petros

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11065460/publications.pdf

Version: 2024-02-01

47 papers	7,021 citations	236612 25 h-index	264894 42 g-index
47 all docs	47 docs citations	47 times ranked	8107 citing authors

#	Article	IF	Citations
1	Machine Learning-Enabled Renal Cell Carcinoma Status Prediction Using Multiplatform Urine-Based Metabolomics. Journal of Proteome Research, 2021, 20, 3629-3641.	1.8	22
2	Urine-Based Metabolomics and Machine Learning Reveals Metabolites Associated with Renal Cell Carcinoma Stage. Cancers, 2021, 13, 6253.	1.7	10
3	Liver-Targeting Class I Selective Histone Deacetylase Inhibitors Potently Suppress Hepatocellular Tumor Growth as Standalone Agents. Cancers, 2020, 12, 3095.	1.7	10
4	The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression. Translational Oncology, 2020, 13, 100751.	1.7	17
5	Molecular characteristics and markers of advanced clear cell renal cell carcinoma: Pitfalls due to intratumoral heterogeneity and identification of genetic alterations associated with metastasis. International Journal of Urology, 2020, 27, 790-797.	0.5	7
6	Discovery and mechanisms of host defense to oncogenesis: targeting the Î²-defensin-1 peptide as a natural tumor inhibitor. Cancer Biology and Therapy, 2019, 20, 774-786.	1.5	12
7	Preoperative Metabolic Signatures of Prostate Cancer Recurrence Following Radical Prostatectomy. Journal of Proteome Research, 2019, 18, 1316-1327.	1.8	30
8	Comparative Cost Analysis: Teleurology vs Conventional Face-to-Face Clinics. Urology, 2018, 113, 40-44.	0.5	37
9	Identification of the Transcription Factor Relationships Associated with Androgen Deprivation Therapy Response and Metastatic Progression in Prostate Cancer. Cancers, 2018, 10, 379.	1.7	21
10	Discovery of a Fluorinated Enigmol Analog with Enhanced in Vivo Pharmacokinetic and Anti-Tumor Properties. ACS Medicinal Chemistry Letters, 2016, 7, 537-542.	1.3	20
11	A mitochondrial DNA mutation influences the apoptotic effect of statins on prostate cancer. Prostate, 2015, 75, 1916-1925.	1.2	23
12	Bone metastasis in prostate cancer: Recurring mitochondrial DNA mutation reveals selective pressure exerted by the bone microenvironment. Bone, 2015, 78, 81-86.	1.4	44
13	Mitochondrial DNA mutations in prostate cancer bone metastases. Journal of Nature and Science, 2015, 1, .	1.1	0
14	Targeting L1 cell adhesion molecule expression using liposome-encapsulated siRNA suppresses prostate cancer bone metastasis and growth. Oncotarget, 2014, 5, 9911-9929.	0.8	22
15	Aquaporin-1 Protein Levels Elevated in Fresh Urine of Renal Cell Carcinoma Patients: Potential Use for Screening and Classification of Incidental Renal Lesions. Disease Markers, 2014, 2014, 1-6.	0.6	14
16	von Hippel-Lindau Exonic Methylation Analysis Using MALDI-TOF Mass Spectrometry. Journal of Urology, 2014, 192, 1528-1533.	0.2	5
17	Global Transcriptome Analysis of Formalin-Fixed Prostate Cancer Specimens Identifies Biomarkers of Disease Recurrence. Cancer Research, 2014, 74, 3228-3237.	0.4	111
18	An Inherited Heteroplasmic Mutation in Mitochondrial Gene COI in a Patient with Prostate Cancer Alters Reactive Oxygen, Reactive Nitrogen and Proliferation. BioMed Research International, 2013, 2013, 1-10.	0.9	43

#	Article	IF	Citations
19	RNAseq Analysis of FFPE Radical Prostatectomy Specimens Identifies Predictors of Biochemical Recurrence. FASEB Journal, 2013, 27, 471.8.	0.2	0
20	Mitochondrial Cytochrome c Oxidase Subunit 1 Sequence Variation in Prostate Cancer. Scientifica, 2012, 2012, 1-7.	0.6	18
21	Novel Synthesis and Biological Evaluation of Enigmols as Therapeutic Agents for Treating Prostate Cancer. ACS Medicinal Chemistry Letters, 2011, 2, 438-443.	1.3	33
22	Proteinâ€coding and MicroRNA Biomarkers of Recurrence of Prostate Cancer Following Radical Prostatectomy. FASEB Journal, 2011, 25, .	0.2	0
23	Mitochondrial genotype and breast cancer predisposition. Oncology Reports, 2010, 24, 1521-34.	1.2	26
24	Mitochondrial NADH-dehydrogenase subunit 3 (ND3) polymorphism (A10398G) and sporadic breast cancer in Poland. Breast Cancer Research and Treatment, 2010, 121, 511-518.	1.1	70
25	Molecular Mapping of Tumor Heterogeneity on Clinical Tissue Specimens with Multiplexed Quantum Dots. ACS Nano, 2010, 4, 2755-2765.	7.3	143
26	Prostate Cancer Bone Colonization: Osteomimicry in the Bone Niche. , 2010, , 157-166.		1
27	Mitochondrial DNA mutation stimulates prostate cancer growth in bone stromal environment. Prostate, 2009, 69, 1-11.	1.2	61
28	Sequence variation in the mitochondrial gene cytochrome c oxidase subunit I and prostate cancer in African American men. Prostate, 2009, 69, 956-960.	1.2	32
29	Nox1 Expression Determines Cellular Reactive Oxygen and Modulates c-fos-Induced Growth Factor, Interleukin-8, and Cav-1. American Journal of Pathology, 2007, 171, 2021-2032.	1.9	51
30	Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. Nature Protocols, 2007, 2, 1152-1165.	5.5	472
31	Current trends in molecular classification of adult renal tumors. Urology, 2006, 67, 873-880.	0.5	20
32	Oxidative Stress Induces ADAM9 Protein Expression in Human Prostate Cancer Cells. Cancer Research, 2006, 66, 9519-9526.	0.4	94
33	Human Î²-Defensin-1, a Potential Chromosome 8p Tumor Suppressor: Control of Transcription and Induction of Apoptosis in Renal Cell Carcinoma. Cancer Research, 2006, 66, 8542-8549.	0.4	157
34	In vivo molecular and cellular imaging with quantum dots. Current Opinion in Biotechnology, 2005, 16, 63-72.	3.3	1,131
35	Molecular Classification of Renal Tumors by Gene Expression Profiling. Journal of Molecular Diagnostics, 2005, 7, 206-218.	1.2	130
36	Increased Nox1 and hydrogen peroxide in prostate cancer. Prostate, 2005, 62, 200-207.	1.2	309

#	Article	IF	Citations
37	mtDNA mutations increase tumorigenicity in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 719-724.	3.3	763
38	Cancer-Specific Loss of Î²-Defensin 1 in Renal and Prostatic Carcinomas. Laboratory Investigation, 2003, 83, 501-505.	1.7	110
39	Beta Defensin-1, Parvalbumin, and Vimentin. American Journal of Surgical Pathology, 2003, 27, 199-205.	2.1	111
40	Automated sequencing of complete mitochondrial genomes from laser-capture microdissected samples. BioTechniques, 2003, 35, 606-612.	0.8	7
41	Expression Profiling of Renal Epithelial Neoplasms. American Journal of Pathology, 2001, 158, 1639-1651.	1.9	300
42	Expression of a human cell adhesion molecule, MUC18, in prostate cancer cell lines and tissues. Prostate, 2001, 48, 305-315.	1.2	56
43	Cell-mediated immunity to tumor-associated antigens is a better predictor of survival in early stage breast cancer than stage, grade or lymph node status. Breast Cancer Research and Treatment, 2000, 60, 227-234.	1.1	57
44	Novel mitochondrial DNA deletion found in a renal cell carcinoma. , 1996, 15, 95-101.		140
45	Perioperative hormonal therapy in locally advanced adenocarcinoma of the prostate. Cancer, 1995, 75, 1969-1971.	2.0	3
46	Effects of Rectal Examination, Prostatic Massage, Ultrasonography and Needle Biopsy on Serum Prostate Specific Antigen Levels. Journal of Urology, 1992, 147, 810-814.	0.2	172
47	Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer. New England Journal of Medicine, 1991, 324, 1156-1161.	13.9	2,106